You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Boehringer Ingelheim
McKesson
Express Scripts
AstraZeneca

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Patent: 7,985,549

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,985,549
Title:Method for predicting responsiveness to TNF.alpha. blocking agents
Abstract: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNF.alpha. blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.
Inventor(s): Salier; Jean-Philippe (Les Authieux-Ratieville, FR), Daveau; Maryvonne (Mont-Saint-Aignan, FR), Gauthier-Jauneau; Anne-Christine (Pont de I\'Arche, FR), Vittecoq; Olivier (Saint Ouen de Thouberville, FR), Loet; Xavier Le (Rouen, FR), Daragon; Alain (Rouen, FR), Mejjad; Othmane (Houppeville, FR), Lequerre; Thierry (MontMain, FR)
Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris cedex, FR)
Application Number:12/300,847
Patent Claims:see list of patent claims

Details for Patent 7,985,549

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris cedex, FR) 2026-05-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Dow
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.